ArticleDiabetes, obesity & metabolism2019

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

Richard F Pollock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.